StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
12
Publishing Date
2023 - 05 - 19
1
2023 - 04 - 13
1
2023 - 03 - 30
1
2022 - 11 - 30
1
2022 - 11 - 09
1
2022 - 11 - 01
1
2022 - 10 - 24
1
2022 - 08 - 04
1
2022 - 05 - 12
1
2022 - 05 - 04
1
2022 - 04 - 19
1
2021 - 11 - 10
1
Sector
Health technology
12
Tags
Agreement
3
Application
4
Approval
4
Beauty
3
Biotechnology
15
Brexafemme
11
Candidiasis
2
Cell
2
China
2
Clinical-trials-phase-iii
5
Commercialization
4
Company
3
Conference
9
Congress
3
Corporation
7
Deadline
20
Disease
2
Drug
6
Earnings
2
Events
6
Fda
5
Financial
7
Financial results
5
Food
3
Fungal infection
8
Fungal infections
5
Global
2
Grant
6
Granted
5
Group
3
Health
8
Infection
4
Infections
24
Injection
14
License
3
Market
2
Medical
3
Meeting
2
N/a
114
Nasdaq
3
Offering
5
Ongoing
6
People
2
Pharm-country
12
Phase 3
12
Positive
11
Positive results
3
Potential
4
Preclinical
7
Presentation
5
Report
6
Research
5
Results
19
Scy-247
6
Skin
3
Study
6
Therapeutics
3
Treatment
8
Trial
7
Update
8
Entities
Actinium pharmaceuticals, inc.
19
Amarin corporation plc
14
Amneal pharmaceuticals, inc.
26
Anavex life sciences corp.
12
Annovis bio, inc.
16
Applied dna sciences, inc.
36
Arbutus biopharma corporation
11
Becton, dickinson and company
20
Biohaven pharmaceutical holding company ltd.
16
Bristol-myers squibb company
67
Certara inc
12
Citius pharmaceuticals, inc.
16
Cytosorbents corporation
12
Electrocore, inc.
19
Eli lilly and company
15
Henry schein, inc.
14
Hoth therapeutics, inc.
19
Immunic, inc.
15
In8bio inc
17
Insmed, inc.
21
Intercept pharmaceuticals, inc.
12
Iveric bio, inc.
14
Johnson & johnson
71
Krystal biotech, inc.
12
Legend biotech corporation
20
Lucid diagnostics inc.
17
Marinus pharmaceuticals, inc.
23
Merck & company, inc.
47
Morgan stanley
15
Nanovibronix, inc.
14
Neuronetics, inc.
16
Nrx pharmaceuticals inc
21
Oramed pharmaceuticals inc.
15
Orange
22
Pavmed inc.
17
Pds biotechnology corporation
20
Petros pharmaceuticals inc
16
Pfizer, inc.
34
Ptc therapeutics, inc.
14
Quest diagnostics incorporated
21
Rallybio corp
13
Regeneron pharmaceuticals, inc.
13
Repro med systems, inc.
18
Rocket pharmaceuticals, inc.
15
Sanofi
54
Schrodinger, inc.
22
Scynexis, inc.
12
Seelos therapeutics, inc.
18
Sellas life sciences group, inc.
16
Soligenix, inc.
20
Sonnet biotherapeutics holdings, inc.
14
Teva pharmaceutical industries limited
19
Teva pharmaceutical industries ltd
18
Tg therapeutics, inc.
14
Tonix pharmaceuticals holding corp.
31
Trevena, inc.
16
Trevi therapeutics, inc.
12
Urogen pharma ltd.
25
Virpax pharmaceuticals inc
17
Y-mabs therapeutics, inc.
22
Symbols
GSK
1
SCYX
12
SPRO
1
TTOO
1
Exchanges
Nasdaq
12
Nyse
1
Crawled Date
2023 - 05 - 19
1
2023 - 04 - 13
1
2023 - 03 - 30
1
2022 - 11 - 30
1
2022 - 11 - 09
1
2022 - 11 - 01
1
2022 - 10 - 24
1
2022 - 08 - 04
1
2022 - 05 - 12
1
2022 - 05 - 04
1
2022 - 04 - 19
1
2021 - 11 - 10
1
Crawled Time
12:00
1
13:00
6
13:20
1
14:00
2
16:00
1
18:00
1
Source
www.biospace.com
12
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Pharm-country
entities :
Scynexis, inc.
save search
WBB Research Institute Webcast Highlighted the Need For a Global Response to Candida auris and Other Deadly Antimicrobial Resistant Pathogens
Published:
2023-05-19
(Crawled : 16:00)
- biospace.com/
TTOO
A
|
$3.16
6.76%
8.78%
1.2M
|
Health Technology
|
1052.44%
|
O:
0.29%
H:
0.0%
C:
-0.36%
SCYX
|
$1.44
2.04%
73K
|
Health Technology
|
-49.83%
|
O:
-0.7%
H:
0.18%
C:
-1.4%
institute
research
global
pathogens
response
SCYNEXIS to Present Ibrexafungerp Data at the 33rd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) April 15-18 in Denmark
Published:
2023-04-13
(Crawled : 14:00)
- biospace.com/
SCYX
|
$1.44
2.04%
73K
|
Health Technology
|
-53.25%
|
O:
0.0%
H:
9.42%
C:
-1.62%
GSK and SCYNEXIS Announce an Exclusive Agreement to Commercialise and Further Develop Brexafemme (ibrexafungerp), a Novel, First-in-Class Medicine to Treat Fungal Infection
Published:
2023-03-30
(Crawled : 18:00)
- biospace.com/
GSK
|
News
|
$40.59
2.11%
0.57%
3.5M
|
Health Technology
|
15.77%
|
O:
0.0%
H:
0.65%
C:
0.6%
SPRO
|
$1.405
0.36%
0.36%
290K
|
Health Technology
|
-2.76%
|
O:
2.07%
H:
0.0%
C:
-2.7%
SCYX
|
$1.44
2.04%
73K
|
Health Technology
|
-13.77%
|
O:
71.86%
H:
3.48%
C:
2.44%
infection
agreement
brexafemme
fungal infection
SCYNEXIS Announces $3 Million National Institutes of Health Grant Has Been Awarded to Case Western Reserve University Researchers to Study Second Generation Fungerp (SCY-247) to Fight Drug-Resistant Fungi
Published:
2022-11-30
(Crawled : 14:00)
- biospace.com/
SCYX
|
$1.44
2.04%
73K
|
Health Technology
|
-39.5%
|
O:
2.52%
H:
0.0%
C:
-3.28%
scy-247
reserve
grant
health
study
SCYNEXIS Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Published:
2022-11-09
(Crawled : 13:00)
- biospace.com/
SCYX
|
$1.44
2.04%
73K
|
Health Technology
|
-35.71%
|
O:
-1.79%
H:
2.27%
C:
-18.18%
financial
update
results
SCYNEXIS to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 9
Published:
2022-11-01
(Crawled : 13:20)
- biospace.com/
SCYX
|
$1.44
2.04%
73K
|
Health Technology
|
-37.66%
|
O:
2.16%
H:
2.97%
C:
-5.51%
report
financial
update
results
SCYNEXIS Presents Positive Interim Data of Oral Ibrexafungerp for Severe Fungal Infections from Ongoing Phase 3 FURI Study During IDWeek 2022
Published:
2022-10-24
(Crawled : 13:00)
- biospace.com/
SCYX
|
$1.44
2.04%
73K
|
Health Technology
|
-39.75%
|
O:
0.0%
H:
0.76%
C:
-7.11%
ongoing
infections
positive
study
fungal infection
SCYNEXIS Presents Positive Data from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections During the 2022 IDSOG Annual Meeting
Published:
2022-08-04
(Crawled : 13:00)
- biospace.com/
SCYX
|
$1.44
2.04%
73K
|
Health Technology
|
-43.08%
|
O:
1.58%
H:
12.84%
C:
7.0%
meeting
infections
positive
study
SCYNEXIS Reports First Quarter 2022 Financial Results and Provides Corporate Update
Published:
2022-05-12
(Crawled : 12:00)
- biospace.com/
SCYX
|
$1.44
2.04%
73K
|
Health Technology
|
-27.27%
|
O:
-8.59%
H:
9.39%
C:
3.31%
results
SCYNEXIS to Present New Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting
Published:
2022-05-04
(Crawled : 13:00)
- biospace.com/
SCYX
|
$1.44
2.04%
73K
|
Health Technology
|
-45.86%
|
O:
2.26%
H:
0.0%
C:
-4.04%
ongoing
phase 3
SCYNEXIS Secures Additional Commercial Insurance Formulary Coverage for BREXAFEMME® (ibrexafungerp tablets), Providing Access to an Estimated 93 Million Commercially-Insured Lives
Published:
2022-04-19
(Crawled : 13:00)
- biospace.com/
SCYX
|
$1.44
2.04%
73K
|
Health Technology
|
-55.42%
|
O:
-0.31%
H:
2.48%
C:
1.55%
brexafemme
insurance
SCYNEXIS Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Published:
2021-11-10
(Crawled : 13:00)
- biospace.com/
SCYX
|
$1.44
2.04%
73K
|
Health Technology
|
-74.93%
|
O:
3.57%
H:
0.0%
C:
-4.71%
financial results
results
Gainers vs Losers
73%
27%
Top 10 Gainers
MTTR
|
News
M
|
$4.8
175.86%
63.6%
71M
|
AGBA
|
$2.5
100.0%
56.6%
200M
|
Finance
MLEC
|
$2.47
76.43%
42.62%
78M
|
n/a
NUWE
|
$0.334
29.96%
40.99%
2.5M
|
Manufacturing
EDBL
|
News
|
$6.26
66.49%
40.13%
16M
|
ATGL
|
$2.86
46.25%
32.8%
180K
|
ONFO
|
$0.6088
38.68%
27.74%
7.3M
|
n/a
VIVK
|
$1.43
33.65%
27.7%
530K
|
Professional, Scientific, and T...
MNTS
|
$0.5
35.69%
26.3%
4.7M
|
SDIG
A
|
$3.64
35.32%
26.0%
990K
|
Your saved searches
Save your searches and get alerts when important news are released.